- Home
- TCRX vs KNDI Comparison
TCRX vs KNDI Comparison
Compare TCRX & KNDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TCRX | KNDI |
|---|---|---|
| Founded | 2018 | 2002 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.6M | 67.8M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TCRX | KNDI |
|---|---|---|
| Price | $1.01 | $0.84 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 574.3K | 176.9K |
| Earning Date | 03-04-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.28 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,325,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $19.81 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 266.65 | N/A |
| 52 Week Low | $0.88 | $0.78 |
| 52 Week High | $2.57 | $1.77 |
Technical Indicators
Market Signals| Indicator | TCRX | KNDI |
|---|---|---|
| Relative Strength Index (RSI) | 45.55 | 40.25 |
| Support Level | $0.90 | $0.81 |
| Resistance Level | $1.24 | $1.10 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 34.91 | 22.80 |
Price Performance
Historical ComparisonAbout TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About KNDI Kandi Technologies Group Inc
Kandi Technologies Group Inc is engaged in developing, manufacturing, and commercializing fully electric vehicle products and related technologies. Its products mainly consist of EV parts, EV products, and off-road vehicles, including All-Terrain Vehicles (ATVs), UTVs, go-karts, electric scooters, electric self-balancing scooters, and associated parts, and Lithium-ion cells, etc. The company generates maximum revenue from the sale of Off-road vehicles and associated parts. Geographically, it derives maximum revenue from the United States and other countries, followed by China.